CJC-1295 and ipamorelin act on two different receptors, which is exactly why they appear together in so many growth-axis assay designs.
CJC-1295 is a GHRH analog; ipamorelin is a selective ghrelin/GHS-R agonist. Because they engage distinct receptors, published in-vitro work commonly evaluates them together to observe complementary signalling rather than redundant activity.
DAC vs no-DAC
- CJC-1295 with DAC includes a drug-affinity complex that supports albumin binding and a substantially longer half-life.
- CJC-1295 no-DAC (mod GRF 1-29) has a short half-life and is favoured for pulsatile assay designs.
- Select the variant that matches your sampling schedule — mismatches are the most common protocol error we see.
Handling
- Store lyophilized vials at -4°F to 46°F (-20°C to 8°C), protected from light.
- Reconstitute with bacteriostatic water; add solvent slowly down the vial wall, never directly onto the pellet.
- Do not shake — swirl gently until fully dissolved.
- Once reconstituted, keep refrigerated and record the reconstitution date on the vial.
- Log the batch/lot number against the matching COA before any assay work begins.
Every Palm Valley Peptides lot ships from the USA with same-day dispatch on cleared orders, HPLC-MS purity documentation, and a batch-matched certificate of analysis.
Why is ipamorelin described as selective?
In published in-vitro work it shows minimal cross-activity at receptors targeted by earlier-generation GHRPs.
Research use only. Palm Valley Peptides supplies materials strictly for in vitro and laboratory research. Nothing in this article constitutes medical, therapeutic, or dosage advice for human or animal use.
